Aster DM Healthcare & Quality Care Merger to Form Top 3 Indian Hospital Chain
Aster DM Healthcare is merging with Quality Care India Limited to form a top 3 hospital chain in India with over 10,625 beds and ₹8,105 crore revenue. The merged entity will see Aster DM shareholders holding 57.3% stake. Q3FY26 proforma revenue reached ₹2,366 crore (15% YoY growth) and EBITDA ₹503 crore (22% YoY growth).
The merger is a significant corporate action that will substantially alter the company's scale, market position, and financial structure, impacting investors and the healthcare industry.
The merger is expected to create a leading hospital chain with significant scale, improved financial metrics, and potential synergies, leading to positive future prospects.
Aster DM Healthcare Limited has announced the merger of Quality Care India Limited (QCIL) with Aster, creating one of India's top three hospital chains. The merged entity, to be named Aster DM Quality Care Limited, will boast over 10,625 beds and an estimated revenue of ₹8,105 crore. The transaction involves Aster acquiring a 5.0% stake in QCIL from Blackstone and TPG, followed by the merger of QCIL into Aster. The inter-se shareholding will be 57.3% for Aster DM shareholders and 42.7% for Quality Care shareholders. This merger is expected to be EPS accretive from the first full year of operations and is cash neutral. Dr. Azad Moopen will continue as Executive Chairman, with Mr. Varun Khanna appointed as MD & Group CEO and Mr. Sunil Kumar as Group CFO of the merged entity. The combined entity has demonstrated strong performance in Q3FY26, with revenue growing 15% year-on-year to ₹2,366 crore and EBITDA growing 22% year-on-year to ₹503 crore, with EBITDA margins at 21%. Synergies are projected to provide an EBITDA upside potential of 10-15%. The merger is anticipated to be completed by Q1FY27, with NCLT shareholder meetings scheduled between February 27, 2026, and March 13, 2026.
What to do with a filing like this
Aster DM Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under merger. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Healthcare Limited. Read the original for the full detail.